PARP inhibitors (PARPi) as single agents show promise in tumor treatment through the synthetic lethality they induce in cells with defects in BRCA1/BRCA2 and other components of the HR repair pathway [34,35]. The gene discussed is BRCA1; the disease is neoplasm.